Abstract
Interleukin-2-inducible T cell kinase (ITK) is a non-receptor tyrosine kinase expressed in T cells, NKT cells and mast cells which plays a crucial role in regulating the T cell receptor (TCR), CD28, CD2, chemokine receptor CXCR4, and FcηR-mediated signaling pathways. In T cells, ITK is an important mediator for actin reorganization, activation of PLCγ, mobilization of calcium, and activation of the NFAT transcription factor. ITK plays an important role in the secretion of IL-2, but more critically, also has a pivotal role in the secretion of Th2 cytokines, IL-4, IL-5 and IL-13. As such, ITK has been shown to regulate the development of effective Th2 response during allergic asthma as well as infections by parasitic worms. This ability of ITK to regulate Th2 responses, along with its pattern of expression, has led to the proposal that it would represent an excellent target for Th2-mediated inflammation. We discuss here the possibilities and pitfalls of targeting ITK for inflammatory disorders.
Current Topics in Medicinal Chemistry
Title: ITK Inhibitors in Inflammation and Immune-Mediated Disorders
Volume: 9 Issue: 8
Author(s): Nisebita Sahu and Avery August
Affiliation:
Abstract: Interleukin-2-inducible T cell kinase (ITK) is a non-receptor tyrosine kinase expressed in T cells, NKT cells and mast cells which plays a crucial role in regulating the T cell receptor (TCR), CD28, CD2, chemokine receptor CXCR4, and FcηR-mediated signaling pathways. In T cells, ITK is an important mediator for actin reorganization, activation of PLCγ, mobilization of calcium, and activation of the NFAT transcription factor. ITK plays an important role in the secretion of IL-2, but more critically, also has a pivotal role in the secretion of Th2 cytokines, IL-4, IL-5 and IL-13. As such, ITK has been shown to regulate the development of effective Th2 response during allergic asthma as well as infections by parasitic worms. This ability of ITK to regulate Th2 responses, along with its pattern of expression, has led to the proposal that it would represent an excellent target for Th2-mediated inflammation. We discuss here the possibilities and pitfalls of targeting ITK for inflammatory disorders.
Export Options
About this article
Cite this article as:
Sahu Nisebita and August Avery, ITK Inhibitors in Inflammation and Immune-Mediated Disorders, Current Topics in Medicinal Chemistry 2009; 9 (8) . https://dx.doi.org/10.2174/156802609789044443
DOI https://dx.doi.org/10.2174/156802609789044443 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Progress on the In Vivo-In Vitro Correlation (IVIVC) for Immediate Release Dosage Form as an Alternative to Bioavailability Studies
Current Pharmaceutical Analysis IL-4 and IL-13: Their Pathological Roles in Allergic Diseases and their Potential in Developing New Therapies-Update
Medicinal Chemistry Reviews - Online (Discontinued) Sundowning Syndrome: A Possible Marker of Frailty in Alzheimer’s Disease?
CNS & Neurological Disorders - Drug Targets Targeting IL-17 and IL-23 in Immune Mediated Renal Disease
Current Medicinal Chemistry Epigenetic Regulation in Particulate Matter-Mediated Cardiopulmonary Toxicities: A Systems Biology Perspective
Current Pharmacogenomics and Personalized Medicine Advances of Knowledge on Allergic Inflammation and the Oral Mucosa
Recent Patents on Inflammation & Allergy Drug Discovery Targeting Soluble Epoxide Hydrolase for Inflammation and Pain - An Overview of Pharmacology and the Inhibitors
Inflammation & Allergy - Drug Targets (Discontinued) Targeting Mitogen-Activated Protein Kinases for Asthma
Current Drug Targets Molecular Imprinting of Biologically Active Steroidal Systems
Current Organic Chemistry Advances and Patents about Grinding Equipments with Nano-Particle Jet Minimum Quantity Lubrication
Recent Patents on Nanotechnology Hypersensitivity Reactions to Non-Steroidal Anti-Inflammatory Drugs
Current Drug Metabolism Binding Modes and Pharmacophoric Features of Muscarinic Antagonism and β2 Agonism (MABA) Conjugates
Current Topics in Medicinal Chemistry Prospective Function of Different Antioxidant Containing Natural Products in the Treatment of Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Anti-Inflammatory Mechanisms of Glucocorticoids Targeting Granulocytes
Current Drug Targets - Inflammation & Allergy DNAzyme Delivery Approaches in Biological Settings
Current Medicinal Chemistry Biologics: An Update and Challenge of Their Pharmacokinetics
Current Drug Metabolism Editorial [Hot topic: Sleep Abnormalities in Pulmonary Disease (Guest Editor: Shyamsunder Subramanian)]
Current Respiratory Medicine Reviews Chronic Inflammatory Diseases and the Acute Respiratory Distress Syndrome (ARDS)
Current Pharmaceutical Design Mitochondrial Biogenesis: Regulation By Endogenous Gases During Inflammation and Organ Stress
Current Pharmaceutical Design Medications and Recent Patents for Status Asthmaticus in Children
Recent Patents on Inflammation & Allergy Drug Discovery